

Ola Omer Ahmed Mohamed

University of Pennsylvania
Infectious Disease Clinical Trials Unit
3400 Spruce Street
Philadelphia, PA 19104
Ola.Mohamed@Pennmedicine.upenn.edu

Education

October 2021 **United State Medical Licensing Examination USMLE Step 1**

June 2021 **MBBS. Bachelor of Medicine and Bachelor of Surgery, *National University Sudan NUSU***

Professional Experience

Jan/2022 to present Clinical Research Assistant. Perelman school of Medicine *University of Pennsylvania. Philadelphia, PA*

Languages

- Arabic – Native
- English – fluent
- German – intermediate

Professional Certifications

JAN 2022 Good Clinical Practice Course– *Collaborative Institutional Training Initiative (CITI)*

JAN 2022 Human Research Subjects Protection / Biomedical – *Collaborative Institutional Training Initiative (CITI)*

JAN 2021 Health Care Associated Infections, Blue Nile Medical Training Center, Sudan

JAN 2021 Sterilization and Disinfection, Blue Nile Medical Training Center, Sudan

JAN 2021 Quality and Patient Safety, Blue Nile Medical Training Center, Sudan

JAN 2021 Risk Management in Infection Control, Blue Nile Medical Training Center, Sudan

JAN 2021 Surgical Site Infection

OCT 2020 Sudan Basic Life Support BLS, Sudan Medical Specialization Board, Sudan

Computer Skills

- Microsoft Office (Word, Excel, Power Point)
- REDCap
- EPIC
- iMedidata

Clinical Research Study Experience

- **A5128:** Plan for Obtaining Informed Consent to Use Stored Human Biological Materials (HBM) for Currently Unspecified Analyses
- **A5355:** Phase II, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-based anti-Cytomegalovirus (CMV) Vaccine (Triplex®), in Adults with Both Human Immunodeficiency Virus (HIV)-1 and CMV Who Are on Potent Combination ART with Conserved Immune Function
- **A5364:** A Phase I, Open-Label Study of the Safety and Ability of Broadly Neutralizing Antibodies 3BNC117-LS and 10-1074-LS in Combination to Durably Prevent Viral Relapse During a Monitored Analytical Treatment Interruption
- **A5386:** A Phase I Clinical Trial of the Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption
- **CD4CARZFN:** A Pilot Study of T Cells Genetically Modified by Zinc Finger Nucleases and CD4 Chimeric Antigen Receptor in HIV-infected Subjects
- **GS-US-425-6143:** Phase 1b Randomized, Blinded, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GS-8588 in People with HIV-1 who are Virologically Suppressed on Antiretroviral Therapy
- **MCA-1031 (Rockefeller 2):** An open label, single arm study of the safety and antiretroviral activity of the combination of two long-acting broadly neutralizing antibodies plus an IL-15 superagonist complex in ART-treated adults living with HIV during analytical treatment interruption.